Shares of Eli Lilly And Co (NYSE:LLY) have been assigned a consensus recommendation of “Buy” from the nineteen ratings firms that are currently covering the firm, MarketBeat reports. Nine analysts have rated the stock with a hold recommendation and nine have given a buy recommendation to the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $123.12.
A number of equities analysts recently commented on LLY shares. Edward Jones raised Eli Lilly And Co from a “hold” rating to a “buy” rating and set a $117.49 price target for the company in a research note on Tuesday, April 23rd. Guggenheim lowered Eli Lilly And Co from a “buy” rating to a “neutral” rating and set a $125.84 price target for the company. in a research note on Thursday, April 11th. BMO Capital Markets increased their price target on Eli Lilly And Co from $130.00 to $133.00 and gave the company an “outperform” rating in a research note on Wednesday, May 1st. Zacks Investment Research lowered Eli Lilly And Co from a “buy” rating to a “hold” rating in a research note on Tuesday, May 21st. Finally, TheStreet lowered Eli Lilly And Co from a “b+” rating to a “c+” rating in a research note on Thursday, May 9th.
In other Eli Lilly And Co news, CFO Joshua L. Smiley purchased 426 shares of Eli Lilly And Co stock in a transaction dated Wednesday, June 5th. The shares were purchased at an average cost of $118.03 per share, for a total transaction of $50,280.78. Following the completion of the acquisition, the chief financial officer now owns 30,410 shares in the company, valued at approximately $3,589,292.30. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, VP Michael J. Harrington sold 16,000 shares of the stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $116.72, for a total value of $1,867,520.00. Following the completion of the sale, the vice president now owns 110,300 shares in the company, valued at $12,874,216. The disclosure for this sale can be found here. Corporate insiders own 0.11% of the company’s stock.
Shares of NYSE LLY traded up $3.07 during mid-day trading on Tuesday, reaching $111.78. The company’s stock had a trading volume of 2,382,995 shares, compared to its average volume of 4,120,096. The company has a market cap of $106.15 billion, a price-to-earnings ratio of 20.14, a PEG ratio of 1.99 and a beta of 0.19. The company has a quick ratio of 0.85, a current ratio of 1.12 and a debt-to-equity ratio of 5.50. The firm’s fifty day simple moving average is $111.01. Eli Lilly And Co has a 52 week low of $100.22 and a 52 week high of $132.13.
Eli Lilly And Co (NYSE:LLY) last released its quarterly earnings data on Tuesday, July 30th. The company reported $1.50 earnings per share for the quarter, topping analysts’ consensus estimates of $1.45 by $0.05. The firm had revenue of $5.64 billion during the quarter, compared to analyst estimates of $5.59 billion. Eli Lilly And Co had a return on equity of 58.65% and a net margin of 33.76%. The business’s quarterly revenue was up .9% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.48 earnings per share. As a group, equities research analysts anticipate that Eli Lilly And Co will post 5.72 EPS for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 10th. Shareholders of record on Thursday, August 15th will be given a dividend of $0.645 per share. The ex-dividend date is Wednesday, August 14th. This represents a $2.58 dividend on an annualized basis and a yield of 2.31%. Eli Lilly And Co’s dividend payout ratio (DPR) is presently 46.49%.
About Eli Lilly And Co
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Featured Story: What is the G-20?
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.